UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
March 13, 2020
CHEMED CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
Delaware | 1-8351 | 31-0791746 |
(State or other
jurisdiction of
incorporation) | (Commission File Number) | (I.R.S. Employer
Identification
Number) |
2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(513) 762-6690
|
|
|
Title of each class | Trading symbol | Name of each exchange on which registered |
Capital stock $1 par value | CHE | NYSE |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 8.01 Other Events
Chemed Corporation issued a press release announcing that on March 13, 2020, its Board of Directors increased the authorization of Chemed’s share repurchase program to provide for $250 million of future share repurchases. These will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.
A copy of the release is furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
| CHEMED CORPORATION |
|
|
|
Dated: March 13, 2020 | By: | /s/ Michael D. Witzeman |
|
| Michael D. Witzeman |
|
| Vice President and Controller |
|
|
|
